$RGEN
REPLIGEN CORP

2013 Form 10-K Financial Statement

#000119312514099241 Filed on March 14, 2014

View on sec.gov

Income Statement

Concept 2013 2012 Q4 2012 Q3
Revenue $68.17M $18.81M $15.10M
YoY Change 9.48% 162.58% 75.0%
Cost Of Revenue $22.48M $5.920M $6.419M
YoY Change -9.92% 291.79% 206.69%
Gross Profit $45.69M $12.89M $8.685M
YoY Change 22.46% 128.05% 32.84%
Gross Profit Margin 67.02% 68.53% 57.5%
Selling, General & Admin $12.70M $3.253M $3.126M
YoY Change -3.97% -23.78% 25.39%
% of Gross Profit 27.8% 25.23% 35.99%
Research & Development $7.341M $2.343M $2.433M
YoY Change -30.02% -18.36% -20.88%
% of Gross Profit 16.07% 18.17% 28.01%
Depreciation & Amortization $2.092M $920.0K $890.0K
YoY Change -16.05% 100.0% 122.5%
% of Gross Profit 4.58% 7.14% 10.25%
Operating Expenses $20.04M $5.596M $5.559M
YoY Change -15.49% -21.6% -0.16%
Operating Profit $22.87M $6.411M $2.188M
YoY Change 106.38% -516.84% 296.38%
Interest Expense $50.00K $14.00K -$7.000K
YoY Change -11.84% -50.0% -107.0%
% of Operating Profit 0.22% 0.22% -0.32%
Other Income/Expense, Net -$110.0K -$41.00K -$500.0K
YoY Change -516.62% -93.42%
Pretax Income $23.01M $6.418M $1.790M
YoY Change 104.18% -399.07% 195.87%
Income Tax $6.921M -$3.135M -$16.00K
% Of Pretax Income 30.07% -48.85% -0.89%
Net Earnings $16.09M $9.553M $1.806M
YoY Change 13.68% -541.86% 198.51%
Net Earnings / Revenue 23.61% 50.78% 11.96%
Basic Earnings Per Share $0.51 $0.31 $0.06
Diluted Earnings Per Share $0.50 $0.30 $0.06
COMMON SHARES
Basic Shares Outstanding 31.67M shares 31.13M shares 30.95M shares
Diluted Shares Outstanding 32.41M shares 31.60M shares 31.26M shares

Balance Sheet

Concept 2013 2012 Q4 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $61.60M $40.10M $30.30M
YoY Change 53.62% 50.75% -39.16%
Cash & Equivalents $39.80M $29.21M $18.39M
Short-Term Investments $21.80M $10.80M $11.90M
Other Short-Term Assets $900.0K $36.73K $1.100M
YoY Change -43.75% -55.37% 22.22%
Inventory $11.80M $11.14M $10.77M
Prepaid Expenses
Receivables $4.900M $4.159M $7.636M
Other Receivables $7.100M $9.100M $4.000M
Total Short-Term Assets $86.40M $66.21M $53.79M
YoY Change 30.51% 41.19% -10.35%
LONG-TERM ASSETS
Property, Plant & Equipment $12.50M $9.952M $10.12M
YoY Change 25.0% -7.31% 462.02%
Goodwill $994.0K $994.0K
YoY Change 0.0%
Intangibles $7.182M $7.377M
YoY Change -7.87%
Long-Term Investments $12.20M $9.900M $12.40M
YoY Change 23.23% 5.32% 45.88%
Other Assets $400.0K $2.800M $200.0K
YoY Change -85.71% 1300.0% 0.0%
Total Long-Term Assets $32.20M $30.80M $31.10M
YoY Change 4.55% 5.62% 146.86%
TOTAL ASSETS
Total Short-Term Assets $86.40M $66.21M $53.79M
Total Long-Term Assets $32.20M $30.80M $31.10M
Total Assets $118.6M $97.01M $84.90M
YoY Change 22.27% 27.55% 16.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.700M $2.454M $1.767M
YoY Change -32.0% 72.53% 194.45%
Accrued Expenses $7.300M $8.298M $7.269M
YoY Change -5.19% 37.36% 142.3%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.30M $10.75M $9.036M
YoY Change 4.63% 44.06% 115.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.500M $2.133M $1.900M
YoY Change 66.67% -13.61% 216.68%
Total Long-Term Liabilities $3.500M $2.133M $1.900M
YoY Change 66.67% -13.61% 216.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.30M $10.75M $9.036M
Total Long-Term Liabilities $3.500M $2.133M $1.900M
Total Liabilities $14.80M $12.89M $10.94M
YoY Change 14.73% 29.73% 132.68%
SHAREHOLDERS EQUITY
Retained Earnings -$105.2M -$114.7M
YoY Change -11.87%
Common Stock $312.0K $310.5K
YoY Change 1.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $103.9M $84.12M $73.70M
YoY Change
Total Liabilities & Shareholders Equity $118.6M $97.01M $84.90M
YoY Change 22.27% 27.55% 16.94%

Cashflow Statement

Concept 2013 2012 Q4 2012 Q3
OPERATING ACTIVITIES
Net Income $16.09M $9.553M $1.806M
YoY Change 13.68% -541.86% 198.51%
Depreciation, Depletion And Amortization $2.092M $920.0K $890.0K
YoY Change -16.05% 100.0% 122.5%
Cash From Operating Activities $25.93M $7.230M $2.470M
YoY Change 92.94% 48.46% 1546.67%
INVESTING ACTIVITIES
Capital Expenditures $4.635M -$430.0K -$320.0K
YoY Change 266.8% 79.17% 88.24%
Acquisitions
YoY Change
Other Investing Activities -$13.27M $3.570M -$980.0K
YoY Change -423.66% -189.92% -128.91%
Cash From Investing Activities -$17.91M $3.140M -$1.290M
YoY Change -730.31% -174.76% -140.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.522M 270.0K 760.0K
YoY Change 117.61% -330.3%
NET CHANGE
Cash From Operating Activities 25.93M 7.230M 2.470M
Cash From Investing Activities -17.91M 3.140M -1.290M
Cash From Financing Activities 2.522M 270.0K 760.0K
Net Change In Cash 10.55M 10.64M 1.940M
YoY Change -39.53% 1488.06% -36.18%
FREE CASH FLOW
Cash From Operating Activities $25.93M $7.230M $2.470M
Capital Expenditures $4.635M -$430.0K -$320.0K
Free Cash Flow $21.29M $7.660M $2.790M
YoY Change 74.89% 49.9% 771.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
1226000
CY2013Q2 dei Entity Public Float
EntityPublicFloat
262149000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.05
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2823400 shares
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
65987000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11167745
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31195041 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.20
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2315090 shares
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31195041 shares
CY2012Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
98162
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10752228
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1911970
CY2012Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
72000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
12782598
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3634839
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
200000
CY2012Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
5200271
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10326840
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
692212
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
187051253
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2454238
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
418800
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
18307000
CY2012Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2899076
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2133339
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
84124596
CY2012Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1459680
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-105150577
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
599120
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8297990
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
10000
CY2012Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
CY2012Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
329000
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1376877
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1383100
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
311950
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
97010163
CY2012Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
154000
CY2012Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
9914855
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15041000
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
21353000
CY2012Q4 us-gaap Goodwill
Goodwill
994000
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
20745938
CY2012Q4 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
9130515
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7182012
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4158758
CY2012Q4 us-gaap Inventory Net
InventoryNet
11143695
CY2012Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2966900
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3046000
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
20279301
CY2012Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
416580
CY2012Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
12802978
CY2012Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4064317
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
4152000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9952461
CY2012Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
2557384
CY2012Q4 us-gaap Assets
Assets
97010163
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29209821
CY2012Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
1937238
CY2012Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
2974000
CY2012Q4 us-gaap Interest Receivable
InterestReceivable
140363
CY2012Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
30800712
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
36730
CY2012Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4112478
CY2012Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
338814
CY2012Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
20760050
CY2012Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
8565112
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1304887
CY2012Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
10845195
CY2012Q4 us-gaap Prepaid Insurance
PrepaidInsurance
365167
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2160000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
66209451
CY2012Q4 rgen Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
18300
CY2012Q4 rgen Prepaid Services And Professional Fees
PrepaidServicesAndProfessionalFees
747273
CY2012Q4 rgen Capitalized Research And Development Expenses
CapitalizedResearchAndDevelopmentExpenses
15354
CY2012Q4 rgen Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
1367
CY2012Q4 rgen Availableforsale Debt Securities Gross Unrealized Gain Accumulated In Investments
AvailableforsaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments
15479
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31925741 shares
CY2013Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2790204 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
831078 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.07
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1610988 shares
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
687293 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.98
CY2013Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
42 Investment
CY2013Q4 us-gaap Share Price
SharePrice
13.64
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.13
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1518371 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31925741 shares
CY2013Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
7591
CY2013Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
586000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5273000
CY2013Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2902000
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2255000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2273000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11301171
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1998330
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
4525000
CY2013Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
44000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1675185
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3166086
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12287010
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
599784
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
190625937
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
14116000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1721459
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
385478
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1682000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16571000
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1648928
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3457631
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
103886102
CY2013Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
238000
CY2013Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1897473
CY2013Q4 us-gaap Contractual Obligation
ContractualObligation
2326000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-89057422
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3341
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9579712
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2273000
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
10000
CY2013Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
8405000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1090000
CY2013Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2273000
CY2013Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
2028000
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1195248
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2404802
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
319257
CY2013Q4 us-gaap Other Liabilities Fair Value Disclosure
OtherLiabilitiesFairValueDisclosure
0
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
118644904
CY2013Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
183000
CY2013Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2324711
CY2013Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
12218602
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12264000
CY2013Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1000000
CY2013Q4 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
0
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
16802000
CY2013Q4 us-gaap Goodwill
Goodwill
994000
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
187000
CY2013Q4 us-gaap Interest Receivable
InterestReceivable
214902
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
7905877
CY2013Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
32294305
CY2013Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
34017451
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13812307
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
33350
CY2013Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4285648
CY2013Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1000000
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1908109
CY2013Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
21647
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
34012152
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
34017451
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1580000
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
21792154
CY2013Q4 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
6730818
CY2013Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
8973615
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
200000
CY2013Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6187632
CY2013Q4 us-gaap Prepaid Taxes
PrepaidTaxes
135102
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4946132
CY2013Q4 us-gaap Inventory Net
InventoryNet
11798638
CY2013Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1000000
CY2013Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2955120
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
231000
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24796233
CY2013Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1000000
CY2013Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
1984
CY2013Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
13684954
CY2013Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4557870
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
18981000
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3018000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12509223
CY2013Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1000000
CY2013Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
184848
CY2013Q4 us-gaap Assets
Assets
118644904
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
13149147
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39829653
CY2013Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
2116017
CY2013Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
8592434
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1249824
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
21793550
CY2013Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
21793550
CY2013Q4 us-gaap Prepaid Insurance
PrepaidInsurance
344698
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30774467 shares
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.340 pure
us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.000 pure
us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.012 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0238 pure
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.010 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.1540 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2310745
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0125 pure
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.033 pure
us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.043 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.5576 pure
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1520000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
86350599
CY2013Q4 rgen Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
12218602
CY2013Q4 rgen Impact Of Credit Risk On Fair Value Of Derivatives
ImpactOfCreditRiskOnFairValueOfDerivatives
0
CY2013Q4 rgen Available For Sale Securities Debt Maturities One Through Two Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesOneThroughTwoYearsAmortizedCost
12225297
CY2013Q4 rgen Prepaid Services And Professional Fees
PrepaidServicesAndProfessionalFees
521772
CY2013Q4 rgen Marketable Securities Remaining Maturity
MarketableSecuritiesRemainingMaturity
P10M15D
CY2013Q4 rgen Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
9936
CY2013Q4 rgen Availableforsale Debt Securities Gross Unrealized Gain Accumulated In Investments
AvailableforsaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments
4637
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31935541 shares
CY2010Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.08
CY2010Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2566450 shares
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
67086704
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9794509
CY2001Q1 rgen Lease Agreement Term
LeaseAgreementTerm
P10Y
CY2007Q1 rgen Lease Agreement Term
LeaseAgreementTerm
P5Y
CY2008Q1 rgen Lease Agreement Term
LeaseAgreementTerm
P2Y
CY2010Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12526040
CY2011Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14203544
CY2011Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
200000
CY2011Q3 rgen Lease Agreement Term
LeaseAgreementTerm
P11Y
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.5309 pure
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30774467 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
575455
us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
1466000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6338
us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-1845024
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
804000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
694238
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
49465924
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
13215053
us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
248143
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-623094
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1596881
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
107289
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3551969
us-gaap Investment Income Net
InvestmentIncomeNet
161053
us-gaap Revenues
Revenues
23450247
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
190007
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1498998
us-gaap Gain Loss On Investments
GainLossOnInvestments
0
us-gaap Operating Income Loss
OperatingIncomeLoss
-1107067
us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
68926
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-2826
us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
427478
us-gaap Royalty Revenue
RoyaltyRevenue
10235194
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
330867
us-gaap Net Income Loss
NetIncomeLoss
-1612625
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
870252
us-gaap Cost Of Goods Sold
CostOfGoodsSold
5157135
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
15744
us-gaap Costs And Expenses
CostsAndExpenses
24557314
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-330842
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
246587
us-gaap Share Based Compensation
ShareBasedCompensation
730136
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1274597
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3035799
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
528000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
45624819
us-gaap Other Noncash Expense
OtherNoncashExpense
28182
us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
1315315
us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
-32256
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9050382
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15744
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-5092
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
8000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
243182
us-gaap Interest Expense
InterestExpense
27773
us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
52905
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
247222
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-542939
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
11487
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
25
us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
48000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
158000
us-gaap Depreciation
Depreciation
1117000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
730000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
26290378
us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-19287
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5010610
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9461960
rgen Income Tax Reconciliation Gain On Bargain Purchase
IncomeTaxReconciliationGainOnBargainPurchase
112427
rgen Effective Income Tax Rate Reconciliation Transaction Costs
EffectiveIncomeTaxRateReconciliationTransactionCosts
0.151 pure
rgen Deferred Tax Assets Valuation Allowance Increase Decrease
DeferredTaxAssetsValuationAllowanceIncreaseDecrease
73000
rgen Provision For Deferred Income Tax Expense Benefit
ProvisionForDeferredIncomeTaxExpenseBenefit
15744
rgen Income Tax Reconciliation Transaction Costs
IncomeTaxReconciliationTransactionCosts
240842
rgen Income Tax Reconciliation Permanent Differences
IncomeTaxReconciliationPermanentDifferences
218989
rgen Effective Income Tax Rate Reconciliation Bargain Purchase Gain
EffectiveIncomeTaxRateReconciliationBargainPurchaseGain
-0.070 pure
rgen Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.137 pure
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.5758 pure
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30949264 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
170834 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0262 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1787683
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0181 pure
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1771100 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.6360 pure
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30778430 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
317982
us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
1102000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
817000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
450600
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
58095140
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
11810869
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1987178
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
601141
us-gaap Investment Income Net
InvestmentIncomeNet
287430
us-gaap Revenues
Revenues
21384639
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
708311
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1987178
us-gaap Operating Income Loss
OperatingIncomeLoss
1712431
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-31092
us-gaap Share Based Compensation
ShareBasedCompensation
748235
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1274247
us-gaap Royalty Revenue
RoyaltyRevenue
9573770
us-gaap Net Income Loss
NetIncomeLoss
1987178
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
56850
us-gaap Interest Expense
InterestExpense
12683
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-263570
us-gaap Cost Of Goods Sold
CostOfGoodsSold
4186670
us-gaap Costs And Expenses
CostsAndExpenses
19672208
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2731531
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
510000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
54225000
us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
1160775
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5580215
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-291824
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-408224
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-25447
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
25758
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
134000
us-gaap Depreciation
Depreciation
1141000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
748000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4488122
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8744548
CY2007Q2 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
0.01
CY2007Q2 rgen Stock Issued During Period Shares Common Stock Warrants
StockIssuedDuringPeriodSharesCommonStockWarrants
150000 shares
CY2007Q2 rgen Warrant Term
WarrantTerm
P7Y
CY2011 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6338
CY2011 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25
CY2011 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
107289
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-1612625
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
730136
CY2011 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
330867
CY2013 dei Trading Symbol
TradingSymbol
RGEN
CY2013 dei Entity Registrant Name
EntityRegistrantName
REPLIGEN CORP
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0000730272
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.51
CY2013 us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left"><font style="font-family:Times New Roman" size="2"><b>1.</b></font></td> <td align="left" valign="top"><font style="font-family:Times New Roman" size="2"><b>Organization and Nature of Business</b></font></td> </tr> </table> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">Repligen Corporation (&#x201C;Repligen&#x201D; or the &#x201C;Company&#x201D;) is a life sciences company that develops, manufactures and markets high-value, consumable bioprocessing products for life sciences companies and biopharmaceutical manufacturing companies worldwide. The Company is a world-leading manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug. Repligen also supplies several growth factor products used to increase cell culture productivity during the biomanufacturing process. In the expanding area of flexible biomanufacturing technologies, the Company has developed and currently markets a series of OPUS (Open-Platform, User-Specified) chromatography columns for use in clinical-scale manufacturing. The Company generally manufactures and sells Protein A and growth factors to life sciences companies under long-term supply agreements and sells its chromatography columns, as well as media and quality test kits, directly to biopharmaceutical companies or contract manufacturing organizations. Repligen refers to these activities as its bioprocessing business. The Company manufactures its products in production facilities in the United States and Sweden.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"> <font style="font-family:Times New Roman" size="2">Historically, Repligen also conducted activities aimed at developing proprietary therapeutic drug candidates, often with a potential of entering into a collaboration with a larger commercial stage pharmaceutical or biotechnology company in respect of these programs. In addition, the Company has out-licensed certain intellectual property to Bristol-Myers Squibb Company, from which Repligen received royalties on Bristol&#x2019;s net sales in the United States of their product Orencia<font style="font-family:Times New Roman" size="1"><sup style="vertical-align:baseline; position:relative; bottom:.8ex">&#xAE;</sup></font>. On April&#xA0;7, 2008, we entered into a settlement agreement with Bristol in connection with a patent infringement lawsuit that we filed against Bristol. Under the terms of the settlement agreement, Bristol was obligated to pay us royalties on its U.S. net sales of Orencia<font style="font-family:Times New Roman" size="1"><sup style="vertical-align:baseline; position:relative; bottom:.8ex">&#xAE;</sup></font> for any clinical indication at a rate of 1.8% for the first $500,000,000 of annual sales, 2.0% for the next $500,000,000 of annual sales and 4% of annual sales in excess of $1 billion. Under the terms of the agreement, we will not receive any future royalties on Bristol&#x2019;s sales of Orencia<font style="font-family:Times New Roman" size="1"><sup style="vertical-align:baseline; position:relative; bottom:.8ex">&#xAE;</sup></font> made after December&#xA0;31, 2013. As part of Repligen&#x2019;s strategic decision in 2012 to focus the Company&#x2019;s efforts on its core bioprocessing business, the Company reduced efforts on its clinical development programs and increased its efforts to find collaboration partners to finish their development and, if successful, commercialize these therapeutic drug candidates.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The Company is subject to a number of risks typically associated with companies in the biotechnology industry. These risks principally include the Company&#x2019;s dependence on key customers, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with the FDA and other governmental regulations and approval requirements, as well as the ability to grow the Company&#x2019;s business and obtain adequate funding to finance this growth.</font></p> </div>
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.50
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.5139 pure
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32406641 shares
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M28D
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
567052 shares
CY2013 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
739626 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.24
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.004 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.053 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0208 pure
CY2013 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P8Y
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.301 pure
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.0221 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.31
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
25929967
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y3M15D
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0109 pure
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
927654 shares
CY2013 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Concentrations of Credit Risk and Significant Customers</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments that subject the Company to significant concentrations of credit risk primarily consist of cash and cash equivalents, marketable securities and accounts receivable. Per the Company&#x2019;s investment policy, cash equivalents and marketable securities are invested in financial instruments with high credit ratings and credit exposure to any one issue, issuer (with the exception of U.S. treasury obligations) and type of instrument is limited. At December&#xA0;31, 2013 and 2012, the Company had no investments associated with foreign exchange contracts, options contracts or other foreign hedging arrangements.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Concentration of credit risk with respect to accounts receivable is limited to customers to whom the Company makes significant sales. While a reserve for the potential write-off of accounts receivable is maintained, the Company has not written off any significant accounts to date. To control credit risk, the Company performs regular credit evaluations of its customers&#x2019; financial condition.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Revenue from significant customers as a percentage of the Company&#x2019;s total revenue is as follows:</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="56%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years&#xA0;ended&#xA0;December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Nine&#xA0;Months&#xA0;ended&#xA0;December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2010</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Orencia<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="POSITION: relative; BOTTOM: 0.8ex; VERTICAL-ALIGN: baseline">&#xAE;</sup></font> Royalties from Bristol</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">24</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">37</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">37</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Bioprocessing Customer A</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">35</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">42</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">44</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">45</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Bioprocessing Customer B</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Bioprocessing Customer C</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> </table> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Significant accounts receivable balances as a percentage of the Company&#x2019;s total trade accounts receivable and royalties and other receivable balances are as follows:</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="70%"></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,&#xA0;2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,&#xA0;2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Orencia<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="POSITION: relative; BOTTOM: 0.8ex; VERTICAL-ALIGN: baseline">&#xAE;</sup></font> Royalties from Bristol</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">42</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">31</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Bioprocessing Customer A</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Bioprocessing Customer C</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Tenant improvement allowance due from landlord</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Pfizer</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">38</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> </table> </div>
CY2013Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5659000
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
10780000
CY2012Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.30
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.049 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.67
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
91191
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
187000 shares
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Use of Estimates</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#x201C;GAAP&#x201D;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p> </div>
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.39
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4634776
CY2013 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
1589000
CY2013 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-19411
CY2013 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M9D
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.003 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.5363 pure
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31667015 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
343500 shares
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y4M2D
CY2013 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2522185
CY2013 us-gaap Income Taxes Paid
IncomeTaxesPaid
1264000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
991000
CY2013 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-2399697
CY2013 us-gaap Cost Of Goods Sold
CostOfGoodsSold
22481122
CY2013 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
1305388
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1121821
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-733728
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
7824699
CY2013 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2787967
CY2013 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
83706
CY2013 us-gaap Costs And Expenses
CostsAndExpenses
45296383
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2522184
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-508629
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
1059806
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3113892
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10619832
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2437000
CY2013 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1201660
CY2013 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
42480331
CY2013 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
47482382
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
10231223
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-110648
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
23013821
CY2013 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
105771
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
773954
CY2013 us-gaap Investment Income Net
InvestmentIncomeNet
301078
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1637936
CY2013 us-gaap Revenues
Revenues
68169623
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-57604
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
37249
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
16179515
CY2013 us-gaap Gain Loss On Investments
GainLossOnInvestments
0
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
22873240
CY2013 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
74999
CY2013 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1836
CY2013 us-gaap Royalty Revenue
RoyaltyRevenue
20687241
CY2013 us-gaap Net Income Loss
NetIncomeLoss
16093155
CY2013 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
625895
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1059806
CY2013 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses
10000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0
CY2013 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
29208818
CY2013 us-gaap Other Noncash Expense
OtherNoncashExpense
91191
CY2013 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
2682177
CY2013 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
2293245
CY2013 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12701195
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6920666
CY2013 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
73970
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2450220
CY2013 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
3322032
CY2013 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
800000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3723000
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1256736
CY2013 us-gaap Interest Expense
InterestExpense
49849
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0106 pure
CY2012 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P8Y
CY2012 us-gaap Revenues
Revenues
62266536
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.256 pure
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-30266
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
15954380
CY2013 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
71964
CY2013 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1022000
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
4123752
CY2013 us-gaap Depreciation
Depreciation
2092000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1060000
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
1341339
CY2013 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-1227747
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17906289
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7340698
CY2013 rgen Lease Agreement Area
LeaseAgreementArea
45000 sqft
CY2013 rgen Effective Income Tax Rate Reconciliation Transaction Costs
EffectiveIncomeTaxRateReconciliationTransactionCosts
0.000 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350 pure
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
CY2013 rgen Deferred Tax Assets Valuation Allowance Increase Decrease
DeferredTaxAssetsValuationAllowanceIncreaseDecrease
-1736000
CY2013 rgen Provision For Deferred Income Tax Expense Benefit
ProvisionForDeferredIncomeTaxExpenseBenefit
2796914
CY2013 rgen Income Tax Examination Years Subject To Examination
IncomeTaxExaminationYearsSubjectToExamination
March 31, 2008 through 2011
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1263647
CY2013 rgen Number Of Buildings Leased
NumberOfBuildingsLeased
4 Building
CY2013 rgen Income Tax Reconciliation Permanent Differences
IncomeTaxReconciliationPermanentDifferences
-298185
CY2013 rgen Effective Income Tax Rate Reconciliation Bargain Purchase Gain
EffectiveIncomeTaxRateReconciliationBargainPurchaseGain
0.000 pure
CY2013 rgen Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.013 pure
CY2013 rgen Change In Fair Value Of Acquisition Related Contingent Consideration
ChangeInFairValueOfAcquisitionRelatedContingentConsideration
91191
CY2001 rgen Lease Agreement Area
LeaseAgreementArea
25000 sqft
CY2007 rgen Lease Agreement Area
LeaseAgreementArea
2500 sqft
CY2011 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-05-31
CY2011 rgen Lease Agreement Area
LeaseAgreementArea
56000 sqft
CY2012 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.46
CY2012 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.45
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.4976 pure
CY2012 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31253434 shares
CY2012 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
339010 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.000 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.001 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.6450 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.62
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
13439608
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0089 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.032 pure
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1296700 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.006 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.5354 pure
CY2012 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30914424 shares
CY2012 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7792
CY2012 us-gaap Deferred Other Tax Expense Benefit
DeferredOtherTaxExpenseBenefit
3021000
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2884631
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
11175638
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1159064
CY2012 us-gaap Income Taxes Paid
IncomeTaxesPaid
140000
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
931000
CY2012 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
5923675
CY2012 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
39109959
CY2012 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
41834188
CY2012 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
602523
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
95768
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
26403
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
11271406
CY2012 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1790551
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1211343
CY2012 us-gaap Investment Income Net
InvestmentIncomeNet
218604
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10489811
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1384000
CY2012 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2083964
CY2012 us-gaap Interest Expense
InterestExpense
56714
CY2012 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
357866
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1001546
CY2012 us-gaap Gain Loss On Investments
GainLossOnInvestments
0
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
11083113
CY2012 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
67276
CY2012 us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
314244
CY2012 us-gaap Royalty Revenue
RoyaltyRevenue
20432348
CY2012 us-gaap Net Income Loss
NetIncomeLoss
14156037
CY2012 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2734239
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1024152
CY2012 us-gaap Cost Of Goods Sold
CostOfGoodsSold
24957243
CY2012 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
115307
CY2012 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3143268
CY2012 us-gaap Costs And Expenses
CostsAndExpenses
51183423
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1159064
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-7272092
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
1024152
CY2012 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3508592
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
18042076
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2183000
CY2012 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
43214487
CY2012 us-gaap Other Noncash Expense
OtherNoncashExpense
604133
CY2012 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
2213004
CY2012 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
-84265
CY2012 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13226732
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
3944996
CY2012 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1110791
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1159064
CY2012 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-2915673
CY2012 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2012 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1017000
CY2012 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
312630
CY2012 us-gaap Depreciation
Depreciation
2492000
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1024000
CY2012 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-8332
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2840881
CY2012Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31600000 shares
CY2012Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31132000 shares
CY2012Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
9342000
CY2012 rgen Income Tax Reconciliation Gain On Bargain Purchase
IncomeTaxReconciliationGainOnBargainPurchase
82422
CY2012 rgen Effective Income Tax Rate Reconciliation Transaction Costs
EffectiveIncomeTaxRateReconciliationTransactionCosts
0.000 pure
CY2012 rgen Deferred Tax Assets Valuation Allowance Increase Decrease
DeferredTaxAssetsValuationAllowanceIncreaseDecrease
-10169000
CY2012 rgen Provision For Deferred Income Tax Expense Benefit
ProvisionForDeferredIncomeTaxExpenseBenefit
-3197261
CY2012 rgen Income Tax Reconciliation Permanent Differences
IncomeTaxReconciliationPermanentDifferences
242629
CY2012 rgen Number Of Years For Cumulative Pretax Loss Position
NumberOfYearsForCumulativePretaxLossPosition
P3Y
CY2012 rgen Effective Income Tax Rate Reconciliation Bargain Purchase Gain
EffectiveIncomeTaxRateReconciliationBargainPurchaseGain
-0.007 pure
CY2012 rgen Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.021 pure
CY2012 rgen Government Grant
GovernmentGrant
803000
CY2012 rgen Change In Fair Value Of Acquisition Related Contingent Consideration
ChangeInFairValueOfAcquisitionRelatedContingentConsideration
610877
CY2008 rgen Lease Agreement Area
LeaseAgreementArea
7350 sqft
CY2013Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2013Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2013Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31855000 shares
CY2013Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31241000 shares
CY2013Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
11934000
CY2013Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
29000
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3622000
CY2013Q1 us-gaap Revenues
Revenues
16456000
CY2013Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-14000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
3545000
CY2013Q1 us-gaap Royalty Revenue
RoyaltyRevenue
4522000
CY2013Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
62000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
2338000
CY2013Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
6897000
CY2013Q1 us-gaap Costs And Expenses
CostsAndExpenses
12911000
CY2013Q1 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
577000
CY2013Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3308000
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1284000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2183000
CY2013Q1 rgen Change In Fair Value Of Acquisition Related Contingent Consideration
ChangeInFairValueOfAcquisitionRelatedContingentConsideration
-54000
CY2012Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
CY2012Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
CY2012Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31010000 shares
CY2012Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30730000 shares
CY2012Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
109000
CY2012Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1285000
CY2012Q1 us-gaap Revenues
Revenues
12824000
CY2012Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-22000
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1167000
CY2012Q1 us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
314000
CY2012Q1 us-gaap Royalty Revenue
RoyaltyRevenue
3482000
CY2013Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5298000
CY2013Q2 us-gaap Costs And Expenses
CostsAndExpenses
11406000
CY2013Q2 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
643000
CY2012Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
31000
CY2013Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3124000
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1495000
CY2012Q1 us-gaap Costs And Expenses
CostsAndExpenses
11657000
CY2012Q1 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
462000
CY2013Q3 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
724000
CY2012Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
9710000
CY2012Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-41000
CY2013Q2 us-gaap Royalty Revenue
RoyaltyRevenue
4495000
CY2012Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
6418000
CY2013Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
65000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
4539000
CY2012Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3428000
CY2012Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
59000
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2808000
CY2012Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2012Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2012Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31149000 shares
CY2012Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30845000 shares
CY2012Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
11659000
CY2012Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
458000
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1778000
CY2012Q2 us-gaap Revenues
Revenues
15524000
CY2012Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-27000
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1318000
CY2012Q2 us-gaap Royalty Revenue
RoyaltyRevenue
3865000
CY2012Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
29000
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
1570000
CY2012Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
7345000
CY2012Q2 us-gaap Costs And Expenses
CostsAndExpenses
14206000
CY2012Q2 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
537000
CY2012Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3418000
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
208000
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2906000
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.14
CY2013Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
CY2013Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32317000 shares
CY2013Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31644000 shares
CY2013Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
13014000
CY2013Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-122000
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
6034000
CY2013Q2 us-gaap Revenues
Revenues
17509000
CY2013Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-12000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
6103000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2306000
CY2013Q2 rgen Change In Fair Value Of Acquisition Related Contingent Consideration
ChangeInFairValueOfAcquisitionRelatedContingentConsideration
35000
CY2012Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
CY2012Q4 us-gaap Revenues
Revenues
18814000
CY2012Q4 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-14000
CY2012Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
6411000
CY2012Q4 us-gaap Royalty Revenue
RoyaltyRevenue
9104000
CY2012Q4 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
62000
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
9553000
CY2012Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5920000
CY2012Q4 us-gaap Costs And Expenses
CostsAndExpenses
12403000
CY2012Q4 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
620000
CY2012Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
95000
CY2012Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3253000
CY2012Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3135000
CY2012Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2343000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
1806000
CY2012Q4 rgen Change In Fair Value Of Acquisition Related Contingent Consideration
ChangeInFairValueOfAcquisitionRelatedContingentConsideration
267000
CY2013Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.10
CY2012Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
6419000
CY2013Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2012Q3 us-gaap Costs And Expenses
CostsAndExpenses
12916000
CY2013Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32708000 shares
CY2012Q3 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
594000
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32552000 shares
CY2012Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3126000
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
37000
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-16000
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2433000
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31858000 shares
CY2013Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
12184000
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
8143000
CY2013Q3 us-gaap Revenues
Revenues
18822000
CY2013Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31916000 shares
CY2013Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
10350000
CY2013Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-54000
CY2013Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
5215000
CY2013Q4 us-gaap Revenues
Revenues
15382000
CY2013Q4 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-12000
CY2013Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
5183000
CY2013Q4 us-gaap Royalty Revenue
RoyaltyRevenue
5032000
CY2013Q4 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
98000
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
3328000
CY2013Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
4627000
CY2013Q4 us-gaap Costs And Expenses
CostsAndExpenses
10199000
CY2013Q4 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
738000
CY2013Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3367000
CY2013Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1887000
CY2013Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1422000
CY2013Q4 rgen Change In Fair Value Of Acquisition Related Contingent Consideration
ChangeInFairValueOfAcquisitionRelatedContingentConsideration
45000
CY2012Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
CY2012Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31256000 shares
CY2012Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30948000 shares
CY2012Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
11123000
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-500000
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1790000
CY2012Q3 us-gaap Revenues
Revenues
15104000
CY2012Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
7000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
2188000
CY2012Q3 us-gaap Royalty Revenue
RoyaltyRevenue
3981000
CY2012Q3 rgen Change In Fair Value Of Acquisition Related Contingent Consideration
ChangeInFairValueOfAcquisitionRelatedContingentConsideration
344000
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.18
CY2013Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-12000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
8042000
CY2013Q3 us-gaap Royalty Revenue
RoyaltyRevenue
6638000
CY2013Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
76000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
5888000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1430000
CY2013Q3 rgen Change In Fair Value Of Acquisition Related Contingent Consideration
ChangeInFairValueOfAcquisitionRelatedContingentConsideration
65000

Files In Submission

Name View Source Status
0001193125-14-099241-index-headers.html Edgar Link pending
0001193125-14-099241-index.html Edgar Link pending
0001193125-14-099241.txt Edgar Link pending
0001193125-14-099241-xbrl.zip Edgar Link pending
d644889d10k.htm Edgar Link pending
d644889dex1026.htm Edgar Link pending
d644889dex211.htm Edgar Link pending
d644889dex231.htm Edgar Link pending
d644889dex311.htm Edgar Link pending
d644889dex312.htm Edgar Link pending
d644889dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g644889ex10_26pg001.jpg Edgar Link pending
g644889g66h44.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgen-20131231.xml Edgar Link completed
rgen-20131231.xsd Edgar Link pending
rgen-20131231_cal.xml Edgar Link unprocessable
rgen-20131231_def.xml Edgar Link unprocessable
rgen-20131231_lab.xml Edgar Link unprocessable
rgen-20131231_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending